You searched for "age"
Vascular density evaluated by SS-OCTA and microperimetry in RP
The aim of this retrospective, observational cross-sectional one-year study was to evaluate the retinal and choroidal vessel density in the macular area with swept-source optical coherence tomography angiography (SS-OCTA) in patients of retinitis pigmentosa (RP), to compare this data with...The College of Optometrists and AOP support “once-in-a-generation” reform for assessing drivers’ eyesight
The bodies are working together to prepare recommendations for Government on optometry-led mandatory eyesight testing for older drivers. The College of Optometrists and the Association of Optometrists (AOP) will send a clear message to government when they submit their response...
Comparison of the efficacy of anti-VEGFs agents in nvAMD
This retrospective multicentric study conducted in Israel and Canada, compared the efficacy of bevacizumab, aflibercept 2mg and ranibizumab as first-line treatments for neovascular age-related macular degeneration (nvAMD). Included were treatment-naïve nvAMD eyes receiving ≥12 months of treat-and-extend (T&E) anti-VEGF therapy...Moorfields: Implementing a non-medical intravitreal injection service Nov
This highly sought after intravitreal injection course has had a national and global impact by enabling numerous institutions to establish their own non-medical delivered IVT injection services.Moorfields: Implementing a non-medical intravitreal injection service
This highly sought after intravitreal injection course has had a national and global impact by enabling numerous institutions to establish their own non-medical delivered IVT injection services. With an increasing demand in treatment for people with eye conditions such as...Moorfields implementing a non-medical intravitreal injection service
This highly sought after intravitreal injection course has had a national and global impact by enabling numerous institutions to establish their own non-medical delivered IVT injection services. With an increasing demand in treatment for people with eye conditions such as...
Two-year GATHER2 data: anatomical gains, functional questions for avacincaptad pegol in geographic atrophy
Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) remains a leading cause of irreversible central vision loss, and complement dysregulation has long been implicated in its pathogenesis. In 2023, the US FDA approved the first two GA therapies, both...
